May 28 2010
BG Medicine, Inc., a U.S. based, privately-held biomarker discovery and in vitro diagnostics company, announced today that there will be several data presentations regarding galectin-3 at the Heart Failure Congress 2010, the annual scientific meeting of the Heart Failure Association of the European Society of Cardiology, to be held in Berlin, Germany, on May 29th through June 1st. BG Medicine has developed and applied for FDA clearance of an in vitro diagnostic test to measure galectin-3 levels in plasma or serum.
Certain of the data presentations regarding galectin-3 include:
Sponsored Symposium: 'Galectin-3: a novel biomarker of fibrosis in heart failure'
Co-Chairs: Dirk Jan van Veldhuisen (Groningen, NL) and Michael Boehm (Homburg/Saar, DE)
I. Galectin-3 Biology: Remodeling and Progression of Heart Failure — Faiez Zannad (Nancy, FR); Program # 678.
II. Galectin-3 in Heart Failure: Clinical Evidence — Lars Gullestad (Oslo, NO); Program #679.
III. Role of Galectin-3 in the Management of Heart Failure — Dirk Jan van Veldhuisen (Groningen, NL); Program #680.
For further information about the symposium, go to: http://tinyurl.com/2u69fph
Program #234: 'Does the severity of LV dysfunction or the extent of myocardial scar explain elevations in plasma galectin-3 in patients with heart failure?' by Nasser Sherwi, on behalf of John G.F. Cleland and colleagues (Hull, GB). For more information: http://tinyurl.com/358qsr7
Program #612: 'Novel biomarkers of cardiovascular risk prediction and patient segmentation', by Peter Gardiner, Senior Medical Officer, BG Medicine. For more information: http://tinyurl.com/35ae72v